160 related articles for article (PubMed ID: 38542866)
21. Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C.
Yang W; Ge J; Yuan M; Li J; Pan L; Ren J; Dou G; Yang L; Zhou Y; Xie H; Wang X; Hu H
Anticancer Drugs; 2023 Jun; 34(5):609-619. PubMed ID: 36847041
[TBL] [Abstract][Full Text] [Related]
22. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
[TBL] [Abstract][Full Text] [Related]
23. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
24. KRAS K104 modification affects the KRAS
Chen CC; Hsu CY; Lin HY; Zeng HQ; Cheng KH; Wu CW; Tsai EM; Hsieh TH
Sci Rep; 2020 Oct; 10(1):17447. PubMed ID: 33060649
[TBL] [Abstract][Full Text] [Related]
25. Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson-Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis.
Alamri MA; Alawam AS; Alshahrani MM; Kawsar SMA; Prinsa ; Saha S
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446713
[TBL] [Abstract][Full Text] [Related]
26. CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.
Durojaye OA; Ejaz U; Uzoeto HO; Fadahunsi AA; Opabunmi AO; Ekpo DE; Sedzro DM; Idris MO
Amino Acids; 2023 Dec; 55(12):1745-1764. PubMed ID: 37500789
[TBL] [Abstract][Full Text] [Related]
27. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
28. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
29. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
30. Novel natural inhibitors targeting KRAS G12C by computational study.
Jiang Y; Chen W; Wang X; Zhou B; Xie H; Hou Y; Guo Z; Yu B; Zhong S; Su X
Anticancer Drugs; 2022 Oct; 33(9):779-788. PubMed ID: 35980001
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-
Xiao X; Feng J; Ma J; Xia X; Liu X; Zhang J; Ding C; Pang X; Zhang A
J Med Chem; 2023 Nov; 66(22):15524-15549. PubMed ID: 37921024
[TBL] [Abstract][Full Text] [Related]
32. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic high affinity T cell receptor targeting a KRAS
Poole A; Karuppiah V; Hartt A; Haidar JN; Moureau S; Dobrzycki T; Hayes C; Rowley C; Dias J; Harper S; Barnbrook K; Hock M; Coles C; Yang W; Aleksic M; Lin AB; Robinson R; Dukes JD; Liddy N; Van der Kamp M; Plowman GD; Vuidepot A; Cole DK; Whale AD; Chillakuri C
Nat Commun; 2022 Sep; 13(1):5333. PubMed ID: 36088370
[TBL] [Abstract][Full Text] [Related]
34. Site-specific mutagenesis screening in KRAS
Choi J; Shin JY; Kim TK; Kim K; Kim J; Jeon E; Park J; Han YD; Kim KA; Sim T; Kim HK; Kim HS
Cancer Lett; 2024 Jun; 591():216904. PubMed ID: 38642608
[TBL] [Abstract][Full Text] [Related]
35. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
36. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate.
Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA
Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639
[TBL] [Abstract][Full Text] [Related]
37. Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
[TBL] [Abstract][Full Text] [Related]
38. Identification of potential inhibitors, conformational dynamics, and mechanistic insights into mutant Kirsten rat sarcoma virus (G13D) driven cancers.
Tayubi IA; Kumar S U; Doss C GP
J Cell Biochem; 2022 Sep; 123(9):1467-1480. PubMed ID: 35842839
[TBL] [Abstract][Full Text] [Related]
39. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X; Zhang R; Yao J; Mu B; Zhao C
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
[TBL] [Abstract][Full Text] [Related]
40. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA; Han JJW; Lee YH; Lee CS; Luo J
Cancer Res; 2023 Sep; 83(17):2816-2823. PubMed ID: 37339170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
